122 related articles for article (PubMed ID: 38603652)
1. Regorafenib in Patients With Solid Tumors With
Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
[TBL] [Abstract][Full Text] [Related]
2. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract][Full Text] [Related]
4. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib in Patients With Breast Cancer With
Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
J Clin Oncol; 2024 May; ():JCO2302078. PubMed ID: 38748939
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Al Baghdadi T; Alva AS; Dublis SA; Cannon TL; Calfa CJ; Li R; Behl D; Chiu VK; Gold PJ; Marr AS; Mileham KF; Powell SF; Rodon J; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
J Clin Oncol; 2023 Nov; 41(33):5140-5150. PubMed ID: 37561967
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With
Ganti AK; Rothe M; Mangat PK; Garrett-Mayer E; Dib EG; Duvivier HL; Ahn ER; Behl D; Borghaei H; Balmanoukian AS; Gaba A; Li R; Osei-Boateng K; Thota R; Grantham GN; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Jun; 7():e2300041. PubMed ID: 37315265
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher JG; Tait D; Garrett-Mayer E; Halabi S; Mangat PK; Schink JC; Alvarez RH; Veljovich D; Cannon TL; Crilley PA; Pollock T; Calfa CJ; Al Baghdadi T; Thota R; Fleming N; Cotta JA; Rygiel AL; Warren SL; Schilsky RL
Target Oncol; 2020 Dec; 15(6):733-741. PubMed ID: 33090333
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in Patients With Non-Small-Cell Lung Cancer With
Ahn ER; Mangat PK; Garrett-Mayer E; Halabi S; Dib EG; Haggstrom DE; Alguire KB; Calfa CJ; Cannon TL; Crilley PA; Gaba AG; Marr AS; Sangal A; Thota R; Antonelli KR; Islam S; Rygiel AL; Bruinooge SS; Schilsky RL
JCO Precis Oncol; 2020 Nov; 4():757-766. PubMed ID: 35050752
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
13. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Alva AS; Mangat PK; Garrett-Mayer E; Halabi S; Hansra D; Calfa CJ; Khalil MF; Ahn ER; Cannon TL; Crilley P; Fisher JG; Haslem DS; Shrestha S; Antonelli KR; Butler NL; Warren SL; Rygiel AL; Ranasinghe S; Bruinooge SS; Schilsky RL
J Clin Oncol; 2021 Aug; 39(22):2443-2451. PubMed ID: 33844595
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With
Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
[TBL] [Abstract][Full Text] [Related]
17. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]